Skip to main content

Advertisement

SpringerLink
Log in

Effects of interleukin-18 promoter (C607A and G137C) gene polymorphisms and their association with oral squamous cell carcinoma (OSCC) in northern India

  • Research Article
  • Published:
Tumor Biology

Abstract

Interleukin-18 (IL-18) is one of the immunomodulatory cytokines that plays an important role in cellular functions against tumor development and progression. IL-18 (-607) C/A and (-0137) G/C gene promoter polymorphisms and their haplotypes variants are associated with risk of various cancers. We evaluated a possible association of IL-18 (-607) C/A and (-137) G/C gene promoter polymorphisms in the susceptibility to oral squamous cell carcinoma (OSCC). A total number of 272 patients with OSCC and 185 healthy volunteers were genotyped for the IL-18 (-607) C/A and (-137) G/C polymorphism. Polymorphism variants were examined by using tetra-primer amplification refractory mutation system (T-ARMS). Genotype frequencies were evaluated by chi-square test and odds ratio (OR) relative risk. IL-18 (-137) G/C gene polymorphism was significantly associated with the risk of OSCC as compared to healthy volunteers (genotype GG vs GC: OR 2.238; 95 % CI 1.455-3.441; p = 0.0003 and allele G vs C: OR 1.984; 95 % CI 1.335–2.947; p = 0.0007). The genotype and allele frequencies of the IL-18 promoter -607 C/A polymorphism in OSCC patients were not significantly different than that in healthy controls (p > 0.05). Our results suggest that IL-18 -137 G/C polymorphism is significantly associated with the progression of oral cancer but -607 C/A polymorphism is not associated with this.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. World Health Organization. Strengthening the prevention of oral cancer: the WHO perspective. http://www.who.int/oral_health/publications/CDOE05_vol33_397_9/en/ (accessed on 26 Oct 2013)

  2. International Agency for Research on Cancer. GLOBOCAN 2008. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 (accessed on 26 Oct 2013)

  3. Williams HK. Molecular pathogenesis of oral carcinoma. J Clin Pathol. 2000;53:165–72.

    CAS  Google Scholar 

  4. Martone T, Bellone G, Pagano M, Beatrice F, Palonta F, et al. Constitutive expression of interleukin-18 in head and neck squamous carcinoma cells. Head Neck. 2004;26:494–503.

    PubMed  Google Scholar 

  5. Srivastava S, Salim N, Robertson MJ. Interleukin-18: biology and role in the immunotherapy of cancer. Curr Med Chem. 2010;17:3353–7.

    CAS  PubMed  Google Scholar 

  6. Nilkaeo A, Bhuvanath S. Role of interleukin-18 in modulation of oral carcinoma cell proliferation. Mediat Inflamm. 2006;3:67120.

    Google Scholar 

  7. Liu W, Han B, Sun B, Gao Y, Huang Y, et al. Overexpression of interleukin-18 induces growth inhibition, apoptosis and gene expression changes in a human tongue squamous cell carcinoma cell line. J Int Med Res. 2012;40:537–44.

    CAS  PubMed  Google Scholar 

  8. Park S, Cheon S, Cho D. The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol. 2007;4:329–35.

    CAS  PubMed  Google Scholar 

  9. Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol. 2001;112:146–52.

    CAS  PubMed  Google Scholar 

  10. Loyha K, Vatanasapt P, Promthet S, Parkin DM. Risk factors for oral cancer in northeast Thailand. Asian Pac J Cancer Prev. 2012;13:5087–90.

    PubMed  Google Scholar 

  11. Ray JG, Ganguly M, Rao BS, Mukherjee S, Mahato B, et al. Clinico-epidemiological profile of oral potentially malignant and malignant conditions among areca nut, tobacco and alcohol users in Eastern India: a hospital based study. J Oral Maxillofac Pathol. 2013;17:45–50.

    PubMed  PubMed Central  Google Scholar 

  12. Gupta B, Ariyawardana A, Johnson NW. Oral cancer in India continues in epidemic proportions: evidence base and policy initiatives. Int Dent J. 2013;63:12–25.

    PubMed  Google Scholar 

  13. Tsai H-T, Hsin C-H, Hsieh Y-H, Tang C-H, Yang S-F, et al. Impact of interleukin-18 polymorphisms -607A/C and -137G/C on oral cancer occurrence and clinical progression. PLoS One. 2013;8(12):e83572. doi:10.1371/journal.pone.0083572.

    PubMed  PubMed Central  Google Scholar 

  14. Teng YH, Liu TH, Tseng HC, Chung TT, Yeh CM, et al. Contribution of genetic polymorphisms of stromal cell-derived factor-1 and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. Head Neck. 2009;31:1282–8.

    PubMed  Google Scholar 

  15. Chen MK, Chiou HL, Su SC, Chung TT, Tseng HC, et al. The association between hypoxia inducible factor-1alpha gene polymorphisms and increased susceptibility to oral cancer. Oral Oncol. 2009;45:e222–6.

    CAS  PubMed  Google Scholar 

  16. Chen MK, Tsai HT, Chung TT, Su SC, Kao TY, et al. Glutathione S-transferase P1 and alpha gene variants; role in susceptibility and tumor size development of oral cancer. Head Neck. 2010;32:1079–87.

    PubMed  Google Scholar 

  17. Wei YS, Lan Y, Liu YG, Tang H, Tang RG, Wang JC. Interleukin-18 gene promoter polymorphisms and the risk of esophageal squamous cell carcinoma. Acta Oncol. 2007;46:10906.

    Google Scholar 

  18. Liu Y, Lin N, Huang L, Xu Q, Pang G. Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol. 2007;26:6138.

    Google Scholar 

  19. Nikiteas N, Yannopoulos A, Chatzitheofylaktou A, Tsigris C. Heterozygosity for interleukin-18 -607 A/C polymorphism is associated with risk for colorectal cancer. Anticancer Res. 2007;27:384953.

    Google Scholar 

  20. Bushley AW, Ferrell R, McDuffie K, Terada KY, Carney ME, Thompson PJ, et al. Polymorphisms of interleukin [IL]- 1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol. 2004;95:6729.

    Google Scholar 

  21. Vairaktaris E, Serefoglou ZC, Yapijakis C, Agapi C, Vassiliou S, Nkenke E, et al. The interleukin-18 -607A/C polymorphism is not associated with risk for oral cancer. Anticancer Res. 2007;27:4011–4.

    CAS  PubMed  Google Scholar 

  22. Asefi V, Mojtahedi Z, Khademi B, Naeimi S, Ghaderi A. Head and neck squamous cell carcinoma (HNSCC) is not associated with interleukin-18 promoter gene polymorphisms, a case control study. J Laryngol Otol. 2009;123:4448.

    Google Scholar 

  23. Khalili-Azad T, Razmkhah M, Ghiam AF, Doroudchi M, Talei AR, Mojtahedi Z, et al. Association of interleukin-18 gene promoter polymorphisms with breast cancer. Neoplasma. 2009;56:225.

    Google Scholar 

  24. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Taheri M, Hashemi-Shahri SM, Hamzehnejadi M, Naderi M, Moazeni-Roodi A, Bahari G, et al. Lack of association between interleukin-18 -607 C/A gene polymorphism and pulmonary tuberculosis in Zahedan, southeast Iran. Prauge Med Rep. 2012;113:16–22.

    CAS  Google Scholar 

  26. Haghshenas MR, Hosseini SV, Mahmoudi M, Saberi-Firozi M, Farjadian S, Ghaderi A. IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol. 2009;24:1119–22.

    CAS  PubMed  Google Scholar 

  27. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001;12:53–72.

    CAS  PubMed  Google Scholar 

  28. Kim KE, Song H, Kim TS, et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene. 2007;26:1468–76.

    CAS  PubMed  Google Scholar 

  29. Mojtahedi Z. Interleukin (IL)-18 may enhance Th1 response in early cancer but aggravate malignant disease in its later stages. Med Hypotheses. 2005;65:995–6.

    CAS  PubMed  Google Scholar 

  30. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72:1605–21.

    CAS  PubMed  Google Scholar 

  31. Vidal-Vanaclocha F, Mendoza L, Telleria N, Salado C, Valcárcel M, Gallot N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev. 2006;25:417–34.

    CAS  PubMed  Google Scholar 

  32. Lian H, Jin N, Li X, Mi Z, Zhang J, Sun L, et al. Induction of an effective anti-tumor immune response and tumor regression by combined administration of IL-18 and apoptin. Cancer Immunol Immunother. 2007;56:181–92.

    CAS  PubMed  Google Scholar 

  33. Herzyk DJ, Bugelski PJ, Hart TK, Wier PJ. Preclinical safety of recombinant human interleukin-18. Toxicol Pathol. 2003;31:554–61.

    CAS  PubMed  Google Scholar 

  34. Lebel-Binay S, Thiounn N, De Pinieux G, Viellefond A, Debré B, Bonnefoy JY, et al. IL-18 is produced by prostate cancer cells and secreted in response to interferons. Int J Cancer. 2003;106:827–35.

    CAS  PubMed  Google Scholar 

  35. Riedel F, Adam S, Feick P, Haas S, Götte K, Hörmann K. Expression of IL-18 in patients with head and neck squamous cell carcinoma. Int J Mol Med. 2004;13:267–72.

    CAS  PubMed  Google Scholar 

  36. Lissoni P, Brivio F, Rovelli F, Fumagalli G, Malugani F, Vaghi M, et al. Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Boil Regul Homoest Agents. 2000;14:275–7.

    CAS  Google Scholar 

  37. Cao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB. 1999;13:2195–202.

    CAS  Google Scholar 

  38. Golab J. Interleukin-18-interferon Á inducing factor- · novel player in tumor immunotherapy? Cytokine. 2000;12:332–8.

    CAS  PubMed  Google Scholar 

  39. Wang ZY, Gaggero A, Rubartelli A, Rosso O, Miotti S, Mizzanzanica D, et al. Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells. In J Cancer. 2002;98:873–8.

    CAS  Google Scholar 

  40. Nilkaeo A, Bhuvanath S. Role of interleukin-18 in modulation of oral carcinoma cell proliferation. Mediat Inflamm. 2006;3:1–6.

    Google Scholar 

  41. Farjadfar A, Mojtahedi Z, Ghayumi MA. Interleukin-18 promoter polymorphism is associated with lung cancer: a case–control study. Acta Oncol. 2009;48:971–6.

    CAS  PubMed  Google Scholar 

  42. Sobti RC, Shekari M, Tamandani DM, Malekzadeh K, Suri V. Association of interleukin-18 gene promoter polymorphismon the risk of cervix carcinogenesis in North Indian population. Oncol Res. 2008;17:159–66.

    PubMed  Google Scholar 

  43. Jaiswal PK, Singh V, Srivastava P, Mittal RD. Association of IL-12, IL-18 variants and serum IL-18 with bladder cancer susceptibility in North Indian population. Gene. 2013;519:128–34.

    CAS  PubMed  Google Scholar 

  44. Sáenz-López P et al. Impact of interleukin-18 polymorphisms -607 and -137 on clinical characteristics of renal cell carcinoma patients. Hum Immunol. 2010;71:309–13.

    PubMed  Google Scholar 

  45. Farhat K, Hassen E, Bouzgarrou N, Gabbouj S, Bouaouina N, Chouchane L. Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine. 2008;43:132–7.

    CAS  PubMed  Google Scholar 

  46. Naeimi S, Ghiam AF, Mojtahedi Z, Dehaghani AS, Amani D, Ghaderi A. Interleukin-18 gene promoter polymorphisms and recurrent spontaneous abortion. Eur J Obstet Gynecol Reprod Biol. 2006;128:5–9.

    CAS  PubMed  Google Scholar 

  47. Nikiteas N, Yannopoulos A, Chatzitheofylaktou A, Tsigris C. Heterozygosity for interleukin-18 -607A/C polymorphism is associated with risk for colorectal cancer. Anticancer Res. 2007;27:3849–53.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was financially supported by a grant from Indian Council of Medical Research (ICMR).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Anaesthesiology, King George’s Medical University, Lucknow, Uttar Pradesh, 226003, India

    Prithvi Kumar Singh, Rajni Gupta, Jaishri Bogra & Girish Chandra

  2. Department of Biochemistry, King George’s Medical University, Lucknow, Uttar Pradesh, India

    Mohd. Kaleem Ahmad, Syed Rizwan Hussain & Abbas Ali Mahdi

  3. Department of Surgical Oncology, King George’s Medical University, Lucknow, Uttar Pradesh, India

    Vijay Kumar

  4. Department of Microbiology, King George’s Medical University, Lucknow, Uttar Pradesh, India

    Amita Jain

Authors
  1. Prithvi Kumar Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohd. Kaleem Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vijay Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Syed Rizwan Hussain
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rajni Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amita Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Abbas Ali Mahdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jaishri Bogra
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Girish Chandra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Girish Chandra.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, P.K., Ahmad, M.K., Kumar, V. et al. Effects of interleukin-18 promoter (C607A and G137C) gene polymorphisms and their association with oral squamous cell carcinoma (OSCC) in northern India. Tumor Biol. 35, 12275–12284 (2014). https://doi.org/10.1007/s13277-014-2538-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2538-0

Keywords

Search

Navigation